1. Scotland, P.H. (n.d.). Liver disease mortality – Liver disease mortality – Publications – Public Health Scotland. [online] publichealthscotland.scot. Available at: https://publichealthscotland.scot/publications/liver-disease-mortality/liver-disease-mortality/#section-1.
2. Bouttell J, Lewsey J, Geue C, Antony G, Briggs A, McCartney G, et al. (2016) The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. PLoS ONE 11(10): e0162980. https://doi.org/10.1371/journal.pone.0162980
3. British Liver Trust, The alarming impact of liver disease in the UK. Facts and Statistics (2019).
   https://britishlivertrust.org.uk/wp-content/uploads/The-alarming-impact-of-liver-disease-FINAL-June-2019.pdf
4. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38 Suppl 1:2-6. doi:10.1111/liv.13682.
5. Wong VW-S, Adams LA, de Lédinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. doi:10.1038/s41575-018-0014-9.
6. Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018 May-Jun;22(3):421-428. doi: 10.4103/ijem.IJEM_585_17. PMID: 30090738; PMCID: PMC6063173.
7. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. Published online November 15, 2022. doi:10.1016/S2468-1253(22)00317-X
8. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease: Estes et al. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466.
9. Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018 May-Jun;31(3):288-295. doi: 10.20524/aog.2018.0240. Epub 2018 Feb 23. PMID: 29720854; PMCID: PMC5924851.
10. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
11. Carrieri, P, Mourad, A, Marcellin, F, et al. Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. Liver Int. 2022; 42: 984– 994. doi: 10.1111/liv.15209
12. Kwok R, Choi KC, Wong GL-H, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359-1368. doi:10.1136/gutjnl-2015-309265.
13. Vusirikala, A., Thomas, T., Bhala, N. et al. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord 20, 96 (2020). https://doi.org/10.1186/s12902-020-00582-9